Related Experiment Video
Updated: May 7, 2026
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
Predictive biomarkers for cancer therapy with PARP inhibitors
J Michels1, I Vitale2, M Saparbaev3
11] INSERM, U848, Villejuif, France [2] Institut Gustave Roussy, Villejuif, France [3] Université de Paris Sud, Villejuif, France.
Abstract:
Poly(ADP-ribose) polymerase (PARP) inhibitors have raised high expectations for the treatment of multiple malignancies. PARP inhibitors, which can be used as monotherapies or in combination with DNA-damaging agents, are particularly efficient against tumors with defects in DNA repair mechanisms, in particular the homologous recombination pathway, for instance due to BRCA mutations. Thus, deficient DNA repair provides a framework for the success of PARP inhibitors in medical oncology. Here, we review encouraging results obtained in recent clinical trials investigating the safety and efficacy of PARP inhibitors as anticancer agents. We discuss emerging mechanisms of regulation of homologous recombination and how inhibition of DNA repair might be used in cancer therapy. We surmise that the identification of patients that are likely to benefit from PARP inhibition will improve the clinical use of PARP inhibitors in a defined target population. Thus, we will place special emphasis on biomarker discovery.
Insights
Poly(ADP-ribose) polymerase (PARP) inhibitors show promise in treating cancers with DNA repair defects, especially those with BRCA mutations. Identifying suitable patients through biomarkers will enhance the clinical use of these targeted cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Poly(ADP-ribose) polymerase (PARP) inhibitors are a novel class of anticancer agents.
- Their efficacy is particularly noted in tumors with compromised DNA repair pathways, such as homologous recombination deficiency (HRD) often associated with BRCA mutations.
Purpose of the Study:
- To review the safety and efficacy of PARP inhibitors in recent clinical trials.
- To discuss the mechanisms of homologous recombination regulation and DNA repair inhibition in cancer therapy.
- To emphasize the importance of biomarker discovery for patient selection.
Main Methods:
- Review of recent clinical trial data on PARP inhibitors.
- Discussion of molecular mechanisms underlying PARP inhibitor action and resistance.
- Analysis of biomarker strategies for patient stratification.
Main Results:
- PARP inhibitors demonstrate encouraging safety and efficacy profiles in various malignancies.
- Tumors with defects in DNA repair, particularly homologous recombination, are sensitive to PARP inhibition.
- Emerging data highlight the potential of combining PARP inhibitors with DNA-damaging agents.
Conclusions:
- PARP inhibitors represent a significant advancement in targeted cancer therapy.
- Understanding DNA repair mechanisms is crucial for optimizing the use of PARP inhibitors.
- Biomarker-driven patient selection is essential for maximizing clinical benefit and improving outcomes in oncology.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...